Current reports

Current report 17/2024 – Positive Phase II top – line results for CPL’ 36, a PDE10A inhibitor in the treatment of acute schizophrenia

2024-07-05

Current report 11/2024 – Results of phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)

2024-06-17

Current report No. 7/2024 – Opinion of the Supervisory’s Board on the Management Board’s recommendation on the payment of the dividend

2024-06-13

Current report No. 6/2024 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 21, 2024 with draft resolutions

2024-06-13

Current report No. 5/2024 – The Management Board’s recommendation on the payment of the dividend 

2024-06-13

Current report No. 3/2024 – Informing about the medicinal product ZARIXA to the pharmaceutical market regulators

2024-06-13

Current report No. 2/2024 – Appointment of the President of the Management Board for another term

2024-06-13

Current report No. 1/2024 – Planned dates of submitting periodical reports in 2024

2024-06-13

Current report 4/2024 – Celon enters into collaboration agreements with Tang Capital to create Novohale Therapeutics, LLC and advance Falkieri into global Phase 3 development for bipolar depression; and delayed disclosure of confidential information about the signing of a term sheet.

2024-05-22